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Abstract
Background: The standard of care in patients with suspected prostate cancer (PCa) is systematic prostate biopsies.
This approach leads to unnecessary biopsies in patients without PCa and also to the detection of clinical
insignificant PCa. Better tools are wanted. We have evaluated the performance of real-time elastography (RTE)
combined with prostate cancer gene 3 (PCA3) in an initial biopsy setting with the goal of better identifying
patients in need of prostate biopsies.
Methods: 127 patients were included in this study; three were excluded because of not measureable PCA3 score
leading to 124 evaluable patients. A cut-off value of 35 was used for PCA3. All patients were examined with a
Hitachi Preirus with an endfire probe for RTE, a maximum of five targeted biopsies were obtained from suspicious
lesions detected by RTE. All patients then had a 10-core systematic biopsy performed by another urologist unaware
of the RTE results. The study includes follow-up data for a minimum of three years; all available histopathological
data are included in the analysis.
Results: There was a significant difference in PCA3 score: 26.6 for benign disease, 73.6 for cancer patients
(p < 0.001). 70 patients (56 %) were diagnosed with prostate cancer in the study period, 21 (30 %) low-risk,
32 (46 %) intermediate-risk and 17 (24 %) high-risk. RTE and PCA3 were significant markers for predicting
intermediate- and high-risk PCa (p = 0.001). The combination of RTE and PCA3 had a sensitivity of 96 % and a
negative predictive value (NPV) of 90 % for the group of intermediate- and high-risk PCa together and a NPV for
high-risk PCa of 100 %. If both parameters are positive there is a high probability of detecting intermediate- or
high-risk PCa, if both parameters are negative there is only a small chance of missing prostate cancer with
documented treatment benefit.
Conclusions: RTE and PCA3 may be used as pre-biopsy examinations to reduce the number of prostate biopsies.
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Background
The mainstay in the diagnosis of prostate cancer (PCa)
is biopsy-driven by serum prostate-specific antigen
(PSA) and digital rectal examination (DRE). There is
really no level of PSA that excludes PCa, and many
benign prostatic diseases may cause PSA elevation. The
threshold value of PSA for prostate biopsy is arbitrarily
chosen, which is dependent on the age of the patient, life
expectancy and the size of the prostate. It is well recog-
nized that PSA screening results in both the over-
diagnosis and overtreatment of prostate cancer [1–3].
Furthermore, a lot of men with benign disease are going
through prostate biopsy without any beneficial effects.
There is also an increase in biopsy-related infections
because of antibiotic resistant bacteria, and some of
these infections can be lethal [4, 5]. There is a need to
better identify those men not harboring PCa to avoid
unnecessary biopsies and related complications.
Currently, there is little enthusiasm for population-
based PSA screening, and in May 2012 the U.S. Prevent-
ive Services Task Force recommended against routine
PSA screening [6]. Moreover, European Association of
Urology (EAU) Guidelines (2013) do not support pro-
grammed mass PSA screening, while recommending
early detection in well-informed men [7].
To assist in the decision to perform prostate biopsy,
nomograms have been created. The US Food and
Drug Administration has approved prostate cancer
gene 3 (PCA3) as a predictive test prior to perform-
ing a repeat biopsy. PCA3 has shown to enhance the
performance of nomograms based on initial biopsy
results [8, 9].
Standard systematic prostate biopsy is performed by
placing a biopsy needle in 10 to 12 prostate sectors of
the peripheral zone under transrectal ultrasound (US)
guidance. Cancer in the central or anterior part of the
prostate may be overlooked, and insignificant cancer
detected with such biopsy regimens [10].
Imaging techniques, specifically advanced US and
multiparametric MRI (mpMRI), are evolving, and
thereby making it possible to identify areas suspected
of harboring PCa [11, 12]. Targeted biopsy guided by
RTE detects high-grade cancer, although it misses
some significant cancers compared with a systematic
10-core biopsy [13, 14]. mpMRI, together with fusion
into real-time US, is practical for targeted biopsy but
this approach also misses significant PCa [15].
In a prospective series of patients undergoing radical
prostatectomy, the combination of RTE and PCA3
detected 97 % of significant PCa [16]. The present
study was undertaken to evaluate prospectively the
capability of RTE and PCA 3 to predict clinically
significant PCa in patients admitted for initial prostate
biopsy.
Methods
The study was carried out in the outpatient clinic of
the Department of Urology at Haukeland University
Hospital from February 2011 to June 2012. The Regional
Committee for Medical and Health Research Ethics in
Western Norway approved the study.
A total of 127 consecutive patients were included
using active inclusion, with only a very small amount of
patients declining to participate. The inclusion criteria
were a PSA level 3 – 25 ng/ml, age ≤75 years and no
prior biopsies within the last five years, in addition to
the patients being amenable for radical treatment.
At first, DRE was performed in all patients to deter-
mine clinical stage (cT) and to perform the prostatic
massage needed before urine sampling. Before further
evaluation, the first stray urine was captured and trans-
ferred to the transportation tubes needed for the PCA3
analysis. We used Progensa™ PCA3 analysis, and the
tests were analyzed at the Fürst Medical Laboratory in
Oslo, Norway. After the urine test, all patients were
given a single dose of Ciprofloxacin 1 g as an antibiotic
prophylaxis. All patients were examined in the left
decubital position, with the ultrasound procedures being
thoroughly previously described [16]. In brief, all patients
were examined using a Hitachi Preirus Ultrasound ma-
chine with software for RTE. They were first examined
using a V53W transrectal end-fire probe for B-mode
evaluation, determination of prostate volume (Pvol), RTE
and targeted biopsies. The peripheral zone (PZ) of the
prostate was divided in six region of interest (ROI), one at
the base, one at the mid prostate and one at the apex on
each side. All RTE-reproducible hard lesions of more
than 5 mm were allocated to the corresponding ROI.
Furthermore, two to four targeted biopsies were taken
from suspicious ROIs. A CC531 transrectal simul-
taneous biplane probe was used for standard syste-
matic biopsies. In the same setting a different urologist
blinded for the RTE results performed a 10-core syste-
matic biopsy from the six ROIs. The biopsies were fixated
in formaldehyde and analyzed by two uro-pathologists.
Total core length, as well as the length of cancer tissue
and Gleason grade and score, was separately recorded for
each biopsy core.
In the statistical analyses, we included not only the
results and outcomes of the initial biopsy, but also at
least three years of follow-up data for the patients. If
there was a clinically persisting suspicion of PCa after
the initial biopsies, patients were monitored closely
(see Fig. 1). Repeat biopsies were performed in 38 patients
within the next six months, while in 24 patients no repeat
biopsy was performed. Sixteen patients with benign repeat
biopsies went through a mpMRI of the prostate, and in 12
of these we performed targeted biopsies of suspicious
areas by TRUS guided biopsies with a “cognitive fusion” of
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mpMRI. Together with an uro-radiologist, a trained uro-
logist performed such biopsies. All biopsy data were
included in the analyses. Among those 24 patients with no
repeat biopsy, four patients experienced a normalization
of PSA levels at follow-up, six were admitted for TUR-P
with a benign pathology, and in 14 patients benign pros-
tatic hyperplasia was assumed as the reason for a slight
elevation in PSA level. The medical records for these
patients and the registry at our department of pathology
were examined in October 2015 to identify whether PCa
had been diagnosed since the end of inclusion. The mean
observation time for these patients is 46.7 ± 1.5 months
(median 44.4, range 41–55). The medical records for the
14 patients with benign repeat biopsies were also exa-
mined at the same time, though none have had PCa diag-
nosed in this period.
Statistical analyses
Standard descriptive statistics were used and presented
as mean and median. A 95 % confidence interval (CI)
was calculated. Negative predictive value (NPV), positive
predictive value (PPV), sensitivity and specificity were
calculated for RTE by ROI and by patient, for PCA3
using a cut-off value of 35 and for a combination of
both. Different groups were compared using the exact
Chi-square test, a Mann–Whitney U-test and the t-test
for categorical, ordinal and continuous data, respectively.
A multiple logistic regression model was estimated
entering the clinical parameters age, Pvol and PSA alone,
or combined with a dichotomized PCA3 score of 35 and
positive RTE by patient. DRE is commonly used in such
clinical models but we excluded DRE from the model
because DRE and RTE both are parameters expressing
tissue stiffness. The performance of the calculations was
expressed as the area under the curve (AUC) of the
receiver operating curves (ROC). A 95 %CI was calculated
for the AUC and displayed in parenthesis after AUC.
Results
In three patients the urine did not contain enough cells
for the PCA3 analysis resulting in 124 evaluable patients.
A total of 70 (56 %) patients were diagnosed with PCa,
of whom 62 were identified in the initial biopsy setting
and eight patients at the repeat biopsy. The inclusion of
these eight patients did not alter the diagnostic perfor-
mance of RTE by ROI as the sensitivity, specificity, PPV
and NPV were 43, 84, 49 and 80 %, respectively; the false
positive rate was 16 % and the false negative rate 12 %.
According to the European Association of Urology
(EAU) risk stratification, there were 21 (30 %) low-, 32
Fig. 1 Flowchart of the 127 included patients in this study. The numbers indicate the number of patients in each group. Abbreviations: PCA3:
Prostate cancer gene 3; PCa: Prostate cancer; RARP: Robotic assisted radical prostatectomy; AS: Active surveillance; EBRT: External beam radiation
therapy; TUR-P: Transurethral resection of prostate; PSA: Prostate specific antigen
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(46 %) intermediate- and 17 (24 %) high-risk cancers [7].
In the eight patients detected with PCa on the repeat
biopsies six were low-risk and two were intermediate-
risk cancers, there were no high-risk PCa in this group.
The distribution of PSA, PCA3 score, Pvol, age and
proportion of positive DRE for all patients and for
patients with and without PCa is found in Table 1. The
p-values are calculated for the difference between the
groups with PCa and without PCa. The clinical stage,
biopsy Gleason grade and score and risk stratification
according to EAU guidelines are also detailed in Table 1.
RTE was positive in 85 cases and negative in 39 . The
average PCA3 score in patients with PCa was signifi-
cantly higher compared with normal or benign disease
(73.6 vs. 26.6, p < 0.001). For PSA, there were no statis-
tical significant differences between those patients with-
and those without PCa (9.7 vs. 8.3, p = 0.09).
The sensitivity, specificity, PPV and NPV of RTE by
patient, PCA3 at score 35 and the combination of both
for any PCa, for intermediate- and high-risk PCa together,
and for high-risk PCa alone, are shown in Table 2.
In univariate logistic regression analysis a positive RTE
was a highly significant predictor of intermediate- risk
and high-risk PCa (Table 3).
Entering PCA3 and RTE in a clinical model encom-
passing age, PSA and Pvol; PSA, Pvol and PCA3 were
independent predictors of intermediate-risk and high-
risk PCa while RTE showed a tendency toward signifi-
cance (Table 3).
The results of the logistic regression analyses were
also expressed in a ROC curve that yielded an AUC
of 0.826 (0.752-0.899) for the complete model and 0.787
(0.703-0.872) for the clinical model alone (Fig. 2).
To evaluate the clinical impact of the combination of
PCA3 and RTE, we utilized the most commonly used
cut-off value of 35 for PCA3, and allocated the patients
into four groups.
Group 1 included patients for whom both RTE and
PCA3 were positive. Patients with a positive RTE and
negative PCA3 were put into Group 2, and RTE negative
and PCA3 positive patients were allocated to Group 3.
Finally, Group 4 encompassed patients negative for RTE,
Table 1 Patient characteristics of 124 patients of whom 70 were diagnosed with PCa
Variable Total (n = 124) PCa (n = 70) No PCa (n = 54) p-value*
PSA Mean (Median; 95 %CI) 9.1 (7.2; 8.3-9.9) 9.7 (7.7; 8.5-11.0) 8.3 (6.7; 7.2-9.4) 0.090*
PCA3-score Mean (Median; 95 %CI) 53.1 (33.5; 42.9-63.4) 73.6 (53.5; 57.7-89.6) 26.6 (19.0; 19.9-33-2) <0.001*
Prostate volume Mean (Median; 95 %CI) 60.0 (53.0; 54.7-65.4) 49.9 (43.5; 44.7-55.1) 73.2 (66.5; 63.8-82.5) <0.001*
Age Mean (Median; 95 %CI) 64.0 (65.1; 62.9-65.2) 64.9 (65.7; 63.5-66.2) 62.9 (63.0; 61.0-64.9) 0.094*
Positive DRE Number (%) 31 (25 %) 22 (31 %) 9 (17 %) 0,060**
Clinical stage Number (%)
T1c 35 (50 %)
T2a 12 (17 %)
T2b 6 (9 %)
T2c 11 (16 %)
T3a 6 (9 %)
Gleason score Number (%)
3 + 2 = 5 1 (1 %)
3 + 3 = 6 21 (26 %)
3 + 4 = 7a 15 (19 %)
4 + 3 = 7b 9 (11 %)
4 + 4 = 8 5 (6 %)
4 + 5 = 9 4 (5 %)
5 + 4 = 9 2 (2 %)
EAU-risk Number (%)
Low-risk 21 (30 %)
Intermediate-risk 32 (46 %)
High-risk 17 (24 %)
PCa prostate cancer, PSA prostate specific antigen, PCA3 prostate cancer gene 3, DRE digital rectal examination is considered positive if there was suspicion of PCa
*p-value is estimated for the difference of means between the group with PCa and the group without PCa using the t-test
**p-value is estimated for the difference of proportions between the group with PCa and the group without PCa using Chi-square test
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as well as PCA3. Group 1 encompassed 44 patients; 30
had a high- or intermediate-risk PCa, eight a low-risk
PCa and six a benign prostate. If both tests were
positive, we found a high (86 %) probability of PCa at
biopsy. On the other hand, of 23 patients with a PCA3
below 35 and a negative RTE (Group 4), eight patients
were diagnosed with PCa, including six with low-risk
cancer and two with intermediate-risk cancer, while 15
patients did not have any cancer. There was no high-risk
PCa in this group. Omitting a biopsy in this group
would imply a 9 % likelihood of missing PCa of clinical
importance. In Group 2, 14 patients were diagnosed with
cancer and 27 without cancer. There were 16 patients
with a PCA3 score equal to or higher than 35 and a
negative RTE (Group 3); ten patients had cancer and no
cancer was found in the other six. The results achieved
from pre-biopsy PCA3 urinary tests and RTE assess-
ments in both Group 1 and Group 4 are informative and
may be of benefit in the decision-making process as to
whether to perform a biopsy or not.
Out of 70 patients for whom PCa was diagnosed, 27
underwent radical prostatectomy, 27 received external
radiotherapy and 16 opted for active surveillance.
Discussion
There is a changing wind in the way we detect and treat
PCa as a consequence of the well-known over-diagnosis
and overtreatment of PCa, in addition to the documented
increasing rate of post-biopsy infections [4, 5]. There is an
ongoing search for new biomarkers and the development
of improved methods for identifying clinically significant
PCa. Evolving evidences show the benefit of PCA3 in the
decision-making process of performing repeat biopsies in
men where the initial biopsy is negative.
Both RTE and mpMRI are capable of identifying PCa
that is not visualized on B-mode ultrasound [17, 18].
To the best of our knowledge, the present paper is
the first to present prospective data on the combi-
nation of pre-biopsy PCA3 and RTE by patient in pre-
dicting PCa in an unselected series of men admitted
for an initial biopsy.
The most important findings are the high sensitivity as
well as NPV in predicting intermediate-risk and high-
risk PCa (Table 2). PCA3 and RTE appeared to be of
benefit mostly in patients if both parameters were posi-
tive or negative. If both parameters are positive, there is
good reason to perform a biopsy and there is a high
probability of detecting aggressive disease. Additionally,
avoiding a biopsy in which PCA3 and RTE are negative
carries a small risk of missing patients harboring a
clinically significant PCa. In this series we found 32
intermediate-risk PCa and 17 high-risk PCa. By using
RTE and PCA3 as selection criteria for performing a
biopsy, 23 patients would have been advised against
having a biopsy; only two of these patients had
intermediate-risk PCa and no patients had high-risk
PCa. One could argue that the reduction of unneces-
sary biopsies is relatively small since only 23 patients
(19 %) would have been advised against biopsy. On
the other hand, these patients could safely be advised
Table 2 This table shows the diagnostic performance of RTE
and PCA3 score with cut-off 35 for the group of any PCa, for
the combined group of intermediate-and high-risk PCa, and for
high-risk PCa
Parameter Sensitivity Specificity NPV PPV
Any PCa RTE 74 % 39 % 54 % 61 %
PCA3 64 % 78 % 66 % 80 %
Combination 91 % 26 % 70 % 62 %
IR and HR PCa RTE 86 % 43 % 82 % 51 %
PCA3 71 % 66 % 78 % 58 %
Combination 96 % 24 % 90 % 55 %
HR PCa RTE 88 % 35 % 95 % 18 %
PCA3 82 % 57 % 95 % 23 %
Combination 100 % 19 % 100 % 16 %
Abbreviations: PCa prostate cancer, IR intermediate-risk, HR high-risk,
RTE real-time elastography, PCA3 prostate cancer gene 3, NPV negative
predictive value, PPV positive predictive value
Table 3 Logistic regression analyses for predicting high and intermediate risk prostate cancer (n = 124)
Simple Multiple
Unadjusted Fully adjusted Final model
Variables OR 95 % CI p-value** OR 95 % CI p-value** OR 95 % CI p-value**
Age (cont. in years) 1.04 (0.98,1.10) 0.188 1.04 (0.96, 1.13) 0.287
PSA (cont. in ng/ml) 1.18 (1.08, 1.29) <0.001 1.19 (1.07, 1.34) 0.001 1.18 (1.03, 1.14) 0.001
Pvol. (cont. in ml) 0.98 (0.96, 0.99) 0.003 0.97 (0.95, 0.99) 0.005 1.04 (1.04, 1.07) 0.009
Positive RTE (Y/N) 4.46 (1.78, 11.22) 0.001 2.73 (0.96, 7.79) 0.052 2.56 (0.91, 7.23) 0.068
PCA3 (>35 vs. <35) 5.00 (2.28, 10.95) <0.001 3.31 (1.27, 8.63) 0.013 4.12 (1.71, 9.91) 0.001
Abbreviations: RTE: real-time elastography, Cont continuous, Y/N yes/no, OR odds ratio, CI confidence interval, Pvol prostate volume
**p-value by the use of the Likelihood Ratio test
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against biopsy, as every reduction of unnecessary biopsies
is a step in the right direction in reducing over-diagnosis
and overtreatment of low-risk PCa. These findings are in
line with our previous study of the combination of PCA3
and RTE in a smaller series of radically operated PCa
patients [16].
In the logistic regression analysis PCA3 as well as a
positive RTE contributed to the clinical model although
RTE achieved a p-value close to significance (0. 068). In
a ROC analysis, the full model with PCA3 and RTE
achieved an AUC of 0.826. In univariate analysis a
positive RTE is a highly significant predictor of PCa.
No definite threshold of PCA3 score has been agreed
upon as yet, although a score of 35 is most frequently
used as a cut-off value. In our study, we tested two
different PCA3 score thresholds of 21 and 35, respec-
tively. A threshold score of 35 provided the most
optimal PPV of 80 %, which is the same figure found in
a prospective randomized study by Wei et al., using a
PCA3 score threshold of 60 in the initial biopsy setting
[19]. In our analyses, we utilized a PCA3 score of 35 as
the threshold value.
A strength of this study is that it includes histo-
pathological data on initial biopsies, repeat biopsies as well
as data of further follow-up, including mpMRI targeted
biopsies of suspected lesions. No patients in the group
diagnosed with a benign disease have been diagnosed with
PCa in the period since the study inclusion was closed in
June 2012. For all 14 patients with a presumably benign
reason for an elevated PSA, both medical records and
records for the regional pathology laboratory were
checked. We believe that we are as close as possible to the
true prevalence of PCa in the study population at the time
of the examinations. This makes this study different from
other studies investigating PCA3 [8, 20] and RTE [21, 22],
in which the performance of these markers has been solely
evaluated at the initial biopsy.
In this series of patients, a total of 70 patients were
diagnosed with PCa, including 21 who were classified as
low-risk and 49 as either high- or intermediate-risk.
Analyzing the group of PCa patients harboring either
high- or intermediate-risk PCa, the combination of RTE
and PCA3 correctly identified 47 of these patients. That
means we correctly identified 96 % of the patients
harboring PCa in need of treatment in a pre-biopsy
setting. This result may be used to reduce the number of
unnecessary biopsies at a small risk of missing PCa in
need of treatment.
The present study has some limitations. Firstly, it is a
single center, single investigator study. RTE like all US
investigations are real-time examinations and are ope-
rator dependent and an inter-observer investigation
would have been of value. As to the learning curve, it
has been shown that after about 30 RTE the novice is
achieving comparable results to experienced US opera-
tors [23]. Secondly, a relatively small number of patients
are included. Thirdly, there is a limited number of
patients with high-risk PCa, although the findings are in
Fig. 2 ROC curves for the regression analyses for the group of intermediate- and high-risk PCa. The addition of PCA3 score >35 and RTE lead to
an increase in AUC of 0.039. Abbreviations: PCa = Prostate cancer, ROC = receiver operating curves, PCA3 = prostate cancer gene 3, AUC = area
under curve
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line with our previously published paper on patients
planned for radical prostatectomy [16].
Conclusions
In patients with a positive RTE combined with a PCA3
score above 35 there is a high probability of detecting
intermediate- or high-risk PCa. The combination of these
markers correctly identified 47 of 49 (96 %) patients in
need of a further diagnostic work-up. The high NPV of
the combination of PCA3 and RTE makes it possible to
avoid some 20 % of the prostate biopsies without missing
high-risk PCa. If applied to the upper age group, in which
a missing low-risk PCa may be seen as an advantage, the
use of RTE and PCA3 may be implemented as pre-biopsy
examinations to reduce the number of prostate biopsies.
Abbreviations
AUC, area under the curve; CI, confidence interval; DRE, digital rectal
examination; EAU, European Association of Urology; mpMRI, multiparametric
magnetic resonance imaging; NPV, negative predictive value; PCa, prostate
cancer; PCA3, Prostate cancer gene 3; PPV, positive predictive value; PSA,
prostate-specific antigen; Pvol, prostate volume; ROC, receiver operating
curve; RTE, real-time elastography; TRUS, transrectal ultrasound; US,
ultrasound
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